Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Oct 28, 2026

Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Oct 28, 2026

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.

Zacks Investment Research • Oct 27, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue

Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.

The Motley Fool • Oct 27, 2026

The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on pace for management's $500 million non-CF revenue target.

24/7 Wall Street • Oct 26, 2026

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.

Zacks Investment Research • Oct 26, 2026

Baron Health Care Fund: Q3 2026 New Positions And Exits

During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.

Seeking Alpha • Oct 26, 2026

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

The biotech company has grown its annual revenue by more than 600% over the past decade. Kidney disease therapy inaxaplin is seen as a possible blockbuster drug.

The Motley Fool • Oct 24, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Seeking Alpha • Oct 24, 2026